Page 96 - 《中国药房》2020年22期
P. 96

万古霉素持续输注与间歇输注有效性与安全性比较的 Meta 分

        析   Δ


        刘 露 ,吴知桂,范清泽,叶 云,罗宏丽(西南医科大学附属医院药学部,四川 泸州 646000)
               *
                                             #
        中图分类号 R978.1 6         文献标志码 A           文章编号 1001-0408(2020)22-2774-07
                        +
        DOI   10.6039/j.issn.1001-0408.2020.22.15
        摘   要   目的:比较万古霉素持续输注和间歇输注的有效性和安全性,为临床用药提供循证参考。方法:计算机检索 PubMed、
        Cochrane图书馆、Embase、万方数据、中国知网、维普网等数据库,收集万古霉素持续输注(试验组)对比间歇输注(对照组)的随机
        对照研究(RCT)和队列研究,检索时限均为建库起至2020年4月。筛选文献、提取资料后,采用Cochrane 系统评价员手册6.0推
        荐的偏倚风险评估工具对RCT进行质量评价,采用纽卡斯尔-渥太华量表对队列研究进行质量评价;采用Rev Man 5.3软件进行
        Meta分析和发表偏倚分析。结果:共纳入20项研究(3项为RCT、17项为队列研究),共计2 380例患者。Meta分析结果显示,试验
        组患者的目标浓度达标率[RR=1.24,95%CI(1.12,1.38),P<0.000 1]、临床疗效靶值达标率[RR=1.20,95%CI(1.04,1.38),P=
        0.01]均显著高于对照组,肾毒性发生率 [RR=0.56,95%CI(0.45,0.70),P<0.000 01]显著低于对照组;两组患者的治疗有效
        率[RR=1.02,95%CI(0.95,1.10),P=0.53]、用药时间[MD=-0.50,95%CI(-1.40,0.39),P=0.27]、病死率[RR=1.03,95%CI
        (0.78,1.35),P=0.83]比较,差异均无统计学意义。发表偏倚结果显示,以肾毒性发生率为指标时存在发表偏倚的可能性较大。
        结论:万古霉素持续输注能提高患者目标浓度达标率和临床疗效靶值达标率,降低肾毒性发生率,但不能提高治疗有效率;由于发
        表偏倚结果不一致,故上述结论需谨慎解读。
        关键词 万古霉素;持续输注;间歇输注;疗效;安全性;Meta分析

        Efficacy and Safety of Vancomycin Given by Continuous Infusion vs. Intermittent Infusion: A
        Meta-analysis
        LIU Lu,WU Zhigui,FAN Qingze,YE Yun,LUO Hongli(Dept. of Pharmacy,the Affiliated Hospital of
        Southwest Medical University,Sichuan Luzhou 646000,China)

        ABSTRACT    OBJECTIVE:To compare the efficacy and safety of vancomycin given by continuous infusion vs. intermittent
        infusion,and to provide evidence-based reference for clinical drug use. METHODS:Retrieved from PubMed,the Cochrane
        Library,Embase,Wanfang database,CNKI and VIP databases,ranomized controlled trials (RCT) and cohort studies about
        vancomycin given by continuous infusion(trial group)vs. intermittent infusion(control group)were collected during the inception
        to Apr. 2020. After literature screening and data extraction,the qualities of RCTs were evaluated by using bias risk evaluation tool
        recommended by Cochrane system evaluator manual 6.0. The qualities of cohort studies were evaluated by NOS;Rev Man 5.3
        software was used to perform Meta-analysis and publication bias analysis. RESULTS:A total of 20 studies were included(3 RCTs
        and 17 cohort studies),involving 2 380 patients in total. Results of Meta-analysis showed that,target concentration attainment
        rate [RR=1.24,95%CI(1.12,1.38),P<0.000 1] and attainment rate of target clinical efficacy [RR=1.20,95%CI(1.04,1.38),
        P=0.01] of trial group was significantly higher than those of control group. The incidence of nephrotoxicity [RR=0.56,95%CI
        (0.45,0.70),P<0.000 01] was significantly lower than control group. There was no statistical significance in the therapeutic
        efficiency [RR=1.02,95%CI(0.95,1.10),P=0.53],drug treatment duration [MD=-0.50,95%CI(-1.40,0.39),P=0.27] or
        mortality [RR=1.03,95%CI(0.78,1.35),P=0.83] between 2 groups. The results of publication bias showed that the probability
        of publication bias was high when the incidence of nephrotoxicity was used as the index. CONCLUSIONS:Vancomycin continuous
        infusion can improve the attainment rate of target concentration and target clinical efficacy,reduce the incidence of nephrotoxicity,
        but can not improve the treatment efficiency. Due to the inconsistent results of publication bias analysis,the above conclusion needs
        to be interpreted carefully.
        KEYWORDS Vancomycin;Continuous infusion;Intermittent infusion;Efficacy;Safety;Meta-analysis


            Δ 基金项目:四川省省级科技计划项目(No.2017KZ0044)
                                                                万古霉素属于糖肽类抗菌药物,临床应用已超过半
            *药师,硕士研究生。研究方向:临床药学。电话:0830-3165787。
                                                            个世纪,对多种革兰氏阳性菌均有杀灭活性,目前仍为
        E-mail:872867303@qq.com
            # 通信作者:副主任药师,硕士生导师,硕士。研究方向:临床药                  治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染和耐甲
        学。电话:0830-3165787。E-mail:lyfylhl@163.com            氧西林表皮葡萄球菌(MRSE)感染的首选药物,主要用


        ·2774 ·  China Pharmacy 2020 Vol. 31 No. 22                                 中国药房    2020年第31卷第22期
   91   92   93   94   95   96   97   98   99   100   101